NASDAQ · SNDX
Syndax Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SNDX: Nov 02, 2026
Syndax Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/02/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.51. The reported EPS for the same quarter last year was $-0.7.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.51 | $-0.45 | $-0.58 | 6 |
| Dec 2026 | $-0.52 | $-0.43 | $-0.60 | 5 |
| Mar 2027 | $-0.64 | $-0.64 | $-0.64 | 1 |
| Jun 2027 | $-0.55 | $-0.55 | $-0.55 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Barchart · BNK Invest- Zacks · Oct 28, 9:00 AM EDTEarnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineNiagen Bioscience (NAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 26, 9:00 AM EDTSyndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseSyndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- Barchart · Oct 14, 1:48 PM EDTStocks Finish Lower Ahead of Wednesday’s CPI ReportThe S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%. December E-mini S&P futures (ESZ26 ) fell -0.02%, and December E-mini…
- Zacks · Oct 14, 8:52 AM EDTSyndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalSNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
- Barchart · Oct 13, 7:03 PM EDTStocks Decline as Chipmakers RetreatThe S&P 500 Index ($SPX ) (SPY ) is down by -0.13% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.59%. December E-mini S&P futures (ESZ26 ) are down -0.19%, and December E-mini…
- Barchart · Oct 13, 7:03 PM EDTStocks Mixed on Lower Crude Prices and Weakness in ChipmakersThe S&P 500 Index ($SPX ) (SPY ) is up by +0.04% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.37%. December E-mini S&P futures (ESZ26 ) are up +0.04%, and December E-mini…
- BNK Invest · Oct 13, 1:45 PM EDTTuesday Sector Laggards: Biotechnology, Metals & Mining StocksIn trading on Tuesday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Syndax Pharmaceuticals, off about 17% and shares of Greenwich LifeSciences off about 16.1% on the day. Also lagging the market Tuesday ar
- RTTNews · Oct 13, 2:08 AM EDTSyndax's Phase 2 MAXPIRe Trial Of Axatilimab Misses Primary Endpoint In IPF; Shares Plunge(RTTNews) – Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate of decline in forced vital capacity (FVC).
- RTTNews · Oct 13, 1:32 AM EDTSyndax Reports Phase 2 Setback For Axatilimab In Idiopathic Pulmonary Fibrosis(RTTNews) – Syndax Pharmaceuticals Inc. (SNDX) announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualised rate of decline in forced vital capacity (FVC).
- The Motley Fool · Aug 11, 10:45 PM EDTSyndax (SNDX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 4, 11:03 PM EDTSyndax Pharmaceuticals Q2 Earnings Call HighlightsSyndax Pharmaceuticals (NASDAQ:SNDX) reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow. Chief Executive Officer Mich
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Syndax Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.